The competition for recombinant collagen has shifted towards an ecological loop of "technology application consumption": the upstream breaks through production capacity and type limitations through synthetic biology, the midstream opens up the ceiling with three types of equipment and precision medicine, and the downstream relies on domestic brand strength and consumer education to achieve popularization.

It is expected that the market size will reach 108.3 billion yuan in 2027 and exceed 200 billion yuan in 2030, becoming another "global business card" for China in the field of biomaterials after hyaluronic acid.

1. According to structure and function: mainly including Type I, Type II, Type III, Type V, etc. For example, Type I exists in the skin, bones, etc., providing strength support; Type III often coexists with Type I on the skin and blood vessel walls, responsible for maintaining elasticity; Type II is distributed in the articular cartilage,

assisting the cartilage in buffering impact.

2. Recombinant collagen: Produced through genetic engineering technology, collagen genes from humans or other species are introduced into microbial or animal cells and purified through fermentation.

Recombinant human collagen: The amino acid sequence is completely identical to the natural human body and is used in fields such as medicine and beauty;

Recombinant human collagen: highly similar but not identical in sequence, optimized production efficiency, applied in skincare products, medical dressings, etc;   

   

Recombinant collagen, with its advantages of high purity, controllable structure, non allergenicity, and no pathogen risk, has shown great potential in high-end fields such as healthcare and medical aesthetics. 

Its denaturation temperature reaches 72 ℃, much higher than the 40 ℃ of animal sources, making transportation and storage more convenient.   

In terms of market, the Chinese collagen market has shown significant growth: with a scale of 983 million US dollars in 2019, it is expected to reach 1.576 billion US dollars in 2027, and an average annual compound growth rate of 6.54% from 2016 to 2027, higher than the global 5.42%, demonstrating strong development momentum.

The production of recombinant collagen requires a combination of genetic engineering and biochemical processes, with core processes including bacterial culture, fermentation production, cell lysis, separation and purification.

Among them, purification is the key link. It is necessary to remove impurities such as host protein, nucleic acid and endotoxin, while retaining the unique triple helix structure of collagen (the basis for maintaining biological activity). 

Common technologies include salting out, ultrafiltration, ion exchange chromatography, gel filtration, high performance liquid chromatography (HPLC), etc.   

1. In the field of medical aesthetics, three types of medical devices are challenging hyaluronic acid injection fillers to become the core growth point. By 2025, three types of medical devices (such as recombinant collagen fillers) are expected to receive centralized approval. 

With the dual effects of "immediate support+long-term repair", it is expected that the medical aesthetics market will reach 5.65 billion yuan by 2030, partially replacing hyaluronic acid.   

2. Serious medical treatment: wound repair, tissue regeneration in orthopedics, gynecology, and dentistry applications: hair loss treatment (regulating hair follicle stem cells), recombinant collagen scaffolds for 3D bioprinting (such as cartilage repair), drug slow-release carriers (such as anti-cancer drug encapsulation), etc.

3. Consumer upgrading areas: diversified food and personal care oral beauty: collagen peptide beverages combined with anti glycation and probiotics, with a market size of over 8 billion yuan by 2027. 

Personal care extension: Subdivision fields such as scalp care and maternal and child care have emerged to meet the needs of "family health".